July 28, 2016 7:01 PM ET

Biotechnology

Company Overview of Cerapedics, Inc.

Company Overview

Cerapedics, Inc., an orthobiologics company, develops and commercializes its proprietary synthetic small peptide technology platform. It offers i-FACTOR, a peptide enhanced bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. Cerapedics, Inc. was founded in 2000 and is headquartered in Westminster, Colorado.

11025 Dover Street

Suite 1600

Westminster, CO 80021

United States

Founded in 2000

Phone:

303-974-6275

Fax:

303-974-6285

Key Executives for Cerapedics, Inc.

Chief Executive Officer
Age: 53
President and Chief Operating Officer
Age: 48
Vice President of Finance
Director of Quality Systems and Regulatory Affairs
Executive Officer
Compensation as of Fiscal Year 2016.

Cerapedics, Inc. Key Developments

Cerapedics, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 04:00 PM

Cerapedics, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 04:00 PM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States.

Cerapedics, Inc. Presents at Canaccord Genuity 2016 Musculoskeletal Conference, Mar-01-2016 11:00 AM

Cerapedics, Inc. Presents at Canaccord Genuity 2016 Musculoskeletal Conference, Mar-01-2016 11:00 AM. Venue: Hyatt Regency Orlando, 9801 International Drive, Orlando, FL 32819, United States.

Cerapedics Announces Publication of Results from Pivotal IDE Clinical Trial of i-FACTOR™ Bone Graft in the Cervical Spine

Cerapedics announced results from a pivotal FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR™ Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures have been electronically published in the peer-reviewed journal Spine. The research effort led by principal investigator Michael Janssen, DO, Spine Education Research Institute showed that i-FACTOR bone graft demonstrated safety and efficacy while meeting all four U.S. Food and Drug Administration (FDA) mandated non-inferiority success criteria when compared to local autograft in single-level ACDF for cervical radiculopathy. In the prospective, randomized, single-blinded study patients received either autograft (N=154) or i-FACTOR bone graft (N=165) in a cortical ring allograft. Success was determined by non-inferiority in fusion, Neck Disability Index (NDI) and Neurological Success endpoints, and adverse events at 12 month follow-up.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cerapedics, Inc., please visit www.cerapedics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.